Developing broadly protective influenza vaccines remains a major challenge for global public health. Influenza B viruses cause about one-third of all annual influenza virus infections and current vaccines only show moderate effectiveness against matched virus strains, therefore, development of more effective and broadl...
Máté Vadovics, A. Abbad, Temima Yellin et al.· Molecular Therapy· 0 citations
It is demonstrated that the amount of PEG-lipid used in the LNP formulation has a significant impact on humoral immune responses to mRNA-LNP vaccines in mice and can impact memory B cell responses.
Emily F. Daley, Máté Vadovics, F. Coirada et al.· Journal of Immunology· 0 citations
Findings reveal the unique ability of uAbs to selectively deplete abnormal proteins in vitro and in vivo and open the door to peptide-programmable biologic modulators of other disease-causing proteins.
Tianzheng Ye, A. Alamgir, C. Robertus et al.· Science Advances· 0 citations
In conclusion, the cNS1 mRNA vaccine induces cross-serotype humoral and cellular immune responses in mice, highlighting the potential of consensus antigen design to broaden immune recognition of DENV NS1.
Kittipan Tharakhet, E. Prompetchara, Chirayus Khawsang et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.